-
Je něco špatně v tomto záznamu ?
Chemopreventive and Therapeutic Efficacy of Cinnamomum zeylanicum L. Bark in Experimental Breast Carcinoma: Mechanistic In Vivo and In Vitro Analyses
P. Kubatka, M. Kello, K. Kajo, M. Samec, K. Jasek, D. Vybohova, S. Uramova, A. Liskova, V. Sadlonova, L. Koklesova, R. Murin, M. Adamkov, K. Smejkal, E. Svajdlenka, P. Solar, SM. Samuel, M. Kassayova, TK. Kwon, P. Zubor, M. Pec, J. Danko, D....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
1/0136/19, 1/0653/19, and 1/0753/17
Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
APVV-16-0021 and APVV-16-0446
Agentúra na Podporu Výskumu a Vývoja
code ITMS2014 + 313011D103
"Medicínsky univerzitný vedecký park v Košiciach (MediPark, Košice - Fáza II.)",
ITMS: 26220120053
"CENTER OF EXCELLENCE FOR RESEARCH IN PERSONALIZED THERAPY (CEVYPET)",
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2009-03-01
Health & Medicine (ProQuest)
od 1997-01-01
- MeSH
- fytogenní protinádorové látky aplikace a dávkování chemie farmakologie MeSH
- histony metabolismus MeSH
- krysa rodu rattus MeSH
- kůra rostlin chemie MeSH
- lidé MeSH
- MFC-7 buňky MeSH
- mikro RNA genetika MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory prsu farmakoterapie genetika metabolismus MeSH
- oleje prchavé aplikace a dávkování chemie farmakologie MeSH
- oleje rostlin aplikace a dávkování chemie farmakologie MeSH
- proliferace buněk účinky léků MeSH
- skořicovník ceylonský chemie MeSH
- viabilita buněk účinky léků MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- xenogenní modely - testy protinádorové aktivity MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Comprehensive oncology research suggests an important role of phytochemicals or whole plant foods in the modulation of signaling pathways associated with anticancer action. The goal of this study is to assess the anticancer activities of Cinnamomum zeylanicum L. using rat, mouse, and cell line breast carcinoma models. C. zeylanicum (as bark powder) was administered in the diet at two concentrations of 0.1% (w/w) and 1% (w/w) during the whole experiment in chemically induced rat mammary carcinomas and a syngeneic 4T1 mouse model. After autopsy, histopathological and molecular evaluations of mammary gland tumors in rodents were carried out. Moreover, in vitro analyses using MCF-7 and MDA-MB-231 cells were performed. The dominant metabolites present in the tested C. zeylanicum essential oil (with relative content over 1%) were cinnamaldehyde, cinnamaldehyde dimethyl acetal, cinnamyl acetate, eugenol, linalool, eucalyptol, limonene, o-cymol, and α-terpineol. The natural mixture of mentioned molecules demonstrated significant anticancer effects in our study. In the mouse model, C. zeylanicum at a higher dose (1%) significantly decreased tumor volume by 44% when compared to controls. In addition, treated tumors showed a significant dose-dependent decrease in mitotic activity index by 29% (0.1%) and 45.5% (1%) in comparison with the control group. In rats, C. zeylanicum in both doses significantly reduced the tumor incidence by 15.5% and non-significantly suppressed tumor frequency by more than 30% when compared to controls. An evaluation of the mechanism of anticancer action using valid oncological markers showed several positive changes after treatment with C. zeylanicum. Histopathological analysis of treated rat tumor specimens showed a significant decrease in the ratio of high-/low-grade carcinomas compared to controls. In treated rat carcinomas, we found caspase-3 and Bax expression increase. On the other hand, we observed a decrease in Bcl-2, Ki67, VEGF, and CD24 expressions and MDA levels. Assessment of epigenetic changes in rat tumor cells in vivo showed a significant decrease in lysine methylation status of H3K4m3 and H3K9m3 in the high-dose treated group, a dose-dependent increase in H4K16ac levels (H4K20m3 was not changed), down-regulations of miR21 and miR155 in low-dose cinnamon groups (miR22 and miR34a were not modulated), and significant reduction of the methylation status of two out of five gene promoters-ATM and TIMP3 (PITX2, RASSF1, PTEN promoters were not changed). In vitro study confirmed results of animal studies, in that the essential oil of C. zeylanicum displayed significant anticancer efficacy in MCF-7 and MDA-MB-231 cells (using MTS, BrdU, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential analyses). As a conclusion, C. zeylanicum L. showed chemopreventive and therapeutic activities in animal breast carcinoma models that were also significantly confirmed by mechanistic evaluations in vitro and in vivo.
Department of Immunology and School of Medicine Keimyung University Dalseo Gu 42601 Daegu Korea
Department of Medical Biology Faculty of Medicine P J Safarik University 04011 Kosice Slovakia
Department of Pharmacology Faculty of Medicine P J Šafarik University 040 11 Košice Slovakia
OBGY Health and Care Ltd 01001 Zilina Slovakia
Weill Cornell Medicine in Qatar Qatar Foundation Education City 24144 Doha Qatar
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028371
- 003
- CZ-PrNML
- 005
- 20210219151245.0
- 007
- ta
- 008
- 210105s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules25061399 $2 doi
- 035 __
- $a (PubMed)32204409
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovakia. Division of Oncology, Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovakia.
- 245 10
- $a Chemopreventive and Therapeutic Efficacy of Cinnamomum zeylanicum L. Bark in Experimental Breast Carcinoma: Mechanistic In Vivo and In Vitro Analyses / $c P. Kubatka, M. Kello, K. Kajo, M. Samec, K. Jasek, D. Vybohova, S. Uramova, A. Liskova, V. Sadlonova, L. Koklesova, R. Murin, M. Adamkov, K. Smejkal, E. Svajdlenka, P. Solar, SM. Samuel, M. Kassayova, TK. Kwon, P. Zubor, M. Pec, J. Danko, D. Büsselberg, J. Mojzis,
- 520 9_
- $a Comprehensive oncology research suggests an important role of phytochemicals or whole plant foods in the modulation of signaling pathways associated with anticancer action. The goal of this study is to assess the anticancer activities of Cinnamomum zeylanicum L. using rat, mouse, and cell line breast carcinoma models. C. zeylanicum (as bark powder) was administered in the diet at two concentrations of 0.1% (w/w) and 1% (w/w) during the whole experiment in chemically induced rat mammary carcinomas and a syngeneic 4T1 mouse model. After autopsy, histopathological and molecular evaluations of mammary gland tumors in rodents were carried out. Moreover, in vitro analyses using MCF-7 and MDA-MB-231 cells were performed. The dominant metabolites present in the tested C. zeylanicum essential oil (with relative content over 1%) were cinnamaldehyde, cinnamaldehyde dimethyl acetal, cinnamyl acetate, eugenol, linalool, eucalyptol, limonene, o-cymol, and α-terpineol. The natural mixture of mentioned molecules demonstrated significant anticancer effects in our study. In the mouse model, C. zeylanicum at a higher dose (1%) significantly decreased tumor volume by 44% when compared to controls. In addition, treated tumors showed a significant dose-dependent decrease in mitotic activity index by 29% (0.1%) and 45.5% (1%) in comparison with the control group. In rats, C. zeylanicum in both doses significantly reduced the tumor incidence by 15.5% and non-significantly suppressed tumor frequency by more than 30% when compared to controls. An evaluation of the mechanism of anticancer action using valid oncological markers showed several positive changes after treatment with C. zeylanicum. Histopathological analysis of treated rat tumor specimens showed a significant decrease in the ratio of high-/low-grade carcinomas compared to controls. In treated rat carcinomas, we found caspase-3 and Bax expression increase. On the other hand, we observed a decrease in Bcl-2, Ki67, VEGF, and CD24 expressions and MDA levels. Assessment of epigenetic changes in rat tumor cells in vivo showed a significant decrease in lysine methylation status of H3K4m3 and H3K9m3 in the high-dose treated group, a dose-dependent increase in H4K16ac levels (H4K20m3 was not changed), down-regulations of miR21 and miR155 in low-dose cinnamon groups (miR22 and miR34a were not modulated), and significant reduction of the methylation status of two out of five gene promoters-ATM and TIMP3 (PITX2, RASSF1, PTEN promoters were not changed). In vitro study confirmed results of animal studies, in that the essential oil of C. zeylanicum displayed significant anticancer efficacy in MCF-7 and MDA-MB-231 cells (using MTS, BrdU, cell cycle, annexin V/PI, caspase-3/7, Bcl-2, PARP, and mitochondrial membrane potential analyses). As a conclusion, C. zeylanicum L. showed chemopreventive and therapeutic activities in animal breast carcinoma models that were also significantly confirmed by mechanistic evaluations in vitro and in vivo.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a fytogenní protinádorové látky $x aplikace a dávkování $x chemie $x farmakologie $7 D000972
- 650 _2
- $a nádory prsu $x farmakoterapie $x genetika $x metabolismus $7 D001943
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a skořicovník ceylonský $x chemie $7 D002935
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a histony $x metabolismus $7 D006657
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a oleje prchavé $x aplikace a dávkování $x chemie $x farmakologie $7 D009822
- 650 _2
- $a kůra rostlin $x chemie $7 D024301
- 650 _2
- $a oleje rostlin $x aplikace a dávkování $x chemie $x farmakologie $7 D010938
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kello, Martin $u Department of Pharmacology, Faculty of Medicine, P. J. Šafarik University, 040 11 Košice, Slovakia.
- 700 1_
- $a Kajo, Karol $u St. Elisabeth Oncology Institute, Department of Pathology, 812 50 Bratislava, Slovakia. Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
- 700 1_
- $a Samec, Marek $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Jasek, Karin $u Division of Oncology, Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovakia.
- 700 1_
- $a Vybohova, Desanka $u Department of Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Uramova, Sona $u Division of Oncology, Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, 036 01 Martin, Slovakia.
- 700 1_
- $a Liskova, Alena $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Sadlonova, Vladimira $u Department of Microbiology and Immunology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Koklesova, Lenka $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Murin, Radovan $u Department of Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Adamkov, Marian $u Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Smejkal, Karel $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, 612 42 Brno, Czech Republic.
- 700 1_
- $a Svajdlenka, Emil $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, 612 42 Brno, Czech Republic.
- 700 1_
- $a Solar, Peter $u Department of Medical Biology, Faculty of Medicine, P. J. Safarik University, 04011 Kosice, Slovakia.
- 700 1_
- $a Samuel, Samson Mathews $u Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, 24144 Doha, Qatar.
- 700 1_
- $a Kassayova, Monika $u Department of Animal Physiology, Institute of Biology and Ecology, Faculty of Science, P. J. Šafarik University, 04001 Košice, Slovakia.
- 700 1_
- $a Kwon, Taeg Kyu $u Department of Immunology and School of Medicine, Keimyung University, Dalseo-Gu, 42601 Daegu, Korea.
- 700 1_
- $a Žúbor, Pavol, $d 1975- $u OBGY Health & Care, Ltd., 01001 Zilina, Slovakia. $7 xx0117542
- 700 1_
- $a Pec, Martin $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601 Martin, Slovakia.
- 700 1_
- $a Danko, Jan $u Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
- 700 1_
- $a Büsselberg, Dietrich $u Weill Cornell Medicine in Qatar, Qatar Foundation-Education City, 24144 Doha, Qatar.
- 700 1_
- $a Mojzis, Jan $u Department of Pharmacology, Faculty of Medicine, P. J. Šafarik University, 040 11 Košice, Slovakia.
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 25, č. 6 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32204409 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210219151243 $b ABA008
- 999 __
- $a ok $b bmc $g 1608706 $s 1119551
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 25 $c 6 $e 20200319 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a 1/0136/19, 1/0653/19, and 1/0753/17 $p Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- GRA __
- $a APVV-16-0021 and APVV-16-0446 $p Agentúra na Podporu Výskumu a Vývoja
- GRA __
- $a code ITMS2014 + 313011D103 $p "Medicínsky univerzitný vedecký park v Košiciach (MediPark, Košice - Fáza II.)",
- GRA __
- $a ITMS: 26220120053 $p "CENTER OF EXCELLENCE FOR RESEARCH IN PERSONALIZED THERAPY (CEVYPET)",
- LZP __
- $a Pubmed-20210105
